Laparoscopy/robotics studies explore the limits of minimally invasive surgery
Urologists continue to push the limits of minimally invasive surgery, and key papers presented at the AUA meeting will explore the functional and cancer control outcomes associated with minimally invasive and robotic procedures in prostate cancer and renal cell carcinoma. When to use such approaches remains a source of controversy.
This article is part of the State of Urology 2014
Dr. WolfUrologists continue to push the limits of minimally invasive surgery, and key papers presented at the AUA meeting will explore the functional and cancer control outcomes associated with minimally invasive and robotic procedures in prostate cancer and renal cell carcinoma. When to use such approaches remains a source of controversy.
“Urologists continue to struggle to find the right place for surgical robots in our practice,” said J. Stuart Wolf, Jr., MD, professor of urology at the University of Michigan, Ann Arbor. “Additionally, we continue to explore novel concepts to make our procedures more effective, safer, or easier.”
Here are the abstracts Dr. Wolf says to watch for this year:
PD13-02: Long Term Renal Functional Outcomes of Minimally Invasive Partial Nephrectomy (MIPN) for Renal Cell Carcinoma
Anudeep Mukkamala
PD13-09: Development and Initial Porcine and Cadaveric Experience with Three-Dimensional Printing of Endoscopic and Laparoscopic Equipment
Michael del Junco
MP37-06: Multiparametric Magnetic Resonance Imaging and MRI/Ultrasound Fusion-Guided Biopsy Stratify Patients at Risk for Extracapsular Extension at Radical Prostatectomy
Dima Raskolnikov
MP37-07: Comparative effectiveness of robotic-assisted versus open radical prostatectomy cancer control outcomes
Ioana Popa
MP37-13: Use of the Robotic Surgical Platform for Radical Nephrectomy: A National Comparison of Utilization and Complications for Open, Laparoscopic, and Robotic Approaches
Aaron Weinberg
Subscribe to Urology Times to get monthly news from the leading news source for urologists.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Dr. Richard Matulewicz discusses smoking cessation counseling and treatment among urologists
March 31st 2021“Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.
